{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-013587","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.997055+00:00","generated_at":"2026-06-06T19:38:42.422322+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Therapeutics gets FDA approval for ZYNRELEF indication expansion covering 13M annual procedures","bullets":["FDA approved supplemental NDA for ZYNRELEF to include soft tissue and orthopedic surgical procedures, including foot and ankle.","Expanded indication now covers an estimated 13 million procedures annually, an 86% increase over prior indicated procedures.","No unique safety issues identified in new clinical trials for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.","CEO Craig Collard highlights label expansion, CrossLink partnership, and potential VAN approval as transformative for ZYNRELEF."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-013587","json":"https://secwatch.observer/filing/0001193125-24-013587.json","markdown":"https://secwatch.observer/filing/0001193125-24-013587.md","text":"https://secwatch.observer/filing/0001193125-24-013587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312524013587/0001193125-24-013587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312524013587/d626508d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:38:42.422322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}